Quantcast
Last updated on April 17, 2014 at 12:35 EDT

Latest Peptides Stories

c126589f0fab9d80f3ec11961e91c8b21
2009-07-13 13:20:00

Researchers have invented computational tools to decode and rapidly determine whether natural compounds collected in oceans and forests are new"”or if these pharmaceutically promising compounds have already been described and are therefore not patentable.This University of California, San Diego advance will finally enable scientists to rapidly characterize ring-shaped nonribosomal peptides (NRPs)"”a class of natural compounds of intense interest due to their potential to yield or...

966764f12d3b2fd37af493d72c285f48
2009-04-07 13:10:59

New book provides an overview of aptamer development and applications Research and industry are increasingly exploiting the potential of aptamers. As well as their application in research, medical diagnosis and treatment, aptamers are also interesting as a basis for biosensors for use in environmental analysis because their characteristics enable them to identify and bind target molecules as surely as a key fits a lock. In a new book, researchers at the Helmholtz Centre for Environmental...

2009-03-30 10:20:00

Early Use of INTEGRILIN(R) Investigational Dosing is Not Superior to Delayed Provisional Use in Patients with High-Risk Acute Coronary Syndrome, Study Finds KENILWORTH, N.J., March 30 /PRNewswire-FirstCall/ -- In a study presented today at the 58th annual Scientific Sessions of the American College of Cardiology and simultaneously published by The New England Journal of Medicine, researchers reported that a strategy using an upstream, investigational dose of INTEGRILIN(R) (eptifibatide)...

2009-03-30 10:09:00

BASKING RIDGE, N.J., March 30 /PRNewswire/ -- Regado Biosciences today announced that the Company's Chief Executive Officer, David J. Mazzo, Ph.D., will be presenting at the upcoming 16th Annual Future Leaders in the Biotech Industry Conference to be held at the Millennium Broadway Hotel and Conference Center in New York City. Dr. Mazzo's presentation is scheduled to begin on Thursday, April 2, 2009 at 3:00 PM (EDT). A copy of Dr. Mazzo's presentation will also be available on the Company's...

2009-03-26 11:41:33

U.S. scientists say they've identified the genetic machinery responsible for synthesizing thiostrepton, a powerful antibiotic produced by certain bacteria. Georgia Institute of Technology Assistant Professor Wendy Kelly, postdoctoral fellow Chaoxuan Li and graduate student Lisa Pan said the antibiotic, although effective against the methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, thiostrepton has only limited applications in humans because it is not water...

2009-03-06 08:30:00

HENNIGSDORF, Germany, March 6 /PRNewswire/ -- B-R-A-H-M-S Aktiengesellschaft today announced it has submitted 510(k) file to the U.S. Food and Drug Administration (FDA) to market its patented B-R-A-H-M-S MR-proANP Kryptor Test. Atrial Natriuretic Peptide (ANP) is predominantly produced in the atrium of the heart and comprises 98% of the natriuretic peptides in the circulation. ANP is involved in natriuresis, diuresis, vasodilation and cardiovascular homeostasis. Although this peptide...

2009-02-26 09:24:58

The results of a new clinical trial show an injectable gonadotropin-releasing hormone called goserelin can improve long term survival in some women with early breast cancer. The research found two years of goserelin treatment was comparable to two years of a patient taking tamoxifen. Trial data revealed goserelin can reduce long term risk of cancer recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen.  Researchers said two years of goserelin...

2009-02-12 07:30:00

BASKING RIDGE, N.J., Feb. 12 /PRNewswire/ -- Regado Biosciences, Inc. announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 2009 Wharton Healthcare Business Conference in Philadelphia, PA on Friday, February 20, 2009, at 1:35 Eastern Time. Dr. Mazzo's presentation will include a review of the Company's lead development product, REG1, its pipeline and enterprise-level business initiatives. About Regado Biosciences Regado Biosciences is...

2009-01-06 11:27:00

BASKING RIDGE, N.J., Jan. 6 /PRNewswire/ -- Regado Biosciences, Inc. announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2009, at 11:30am Pacific Time (2:30pm Eastern Time). Dr. Mazzo's presentation will include a review of the Company's lead compound in development, the REG1 System, its pipeline and enterprise-level business initiatives....

2008-12-03 15:33:00

- Additional Pipeline Product Agreement Executed to Support ConjuChem's R&D Efforts - MONTREAL and BAGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies Inc. (TSX:CJB) and Novozymes Biopharma UK Ltd., a subsidiary of Novozymes A/S (LSE:NVZ) announced today that the Companies have entered into a long-term Manufacturing and Supply Agreement by which Novozymes Biopharma will exclusively supply its recombinant human albumin, Recombumin(R), for the...